Could statins lower the risk of ovarian cancer?

In the UK, ovarian cancer is the sixth most common cancer in females*. A new study has found evidence to suggest that statins could lower the risk of women developing ovarian cancer. The research led by the University of Bristol, and funded by Cancer Research UK, is published today [18 February] in JAMA.
Source: University of Bristol news - Category: Universities & Medical Training Tags: Health, Research, International; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School, Institutes, Bristol Population Health Science Institute; Press Release Source Type: news

Related Links:

Women who take statins long-term, including those carrying the BRCA1/2 gene mutation, could be less likely to develop ovarian cancer than those who do not, research published in JAMA has suggested.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Women who naturally exhibit lower levels of an enzyme blocked by statins have an estimated 40 per cent lower risk of ovarian cancer, a study by Bristol University found.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Novel pharmacological therapies are in development for cancer, ranging from conventional chemotherapeutic drugs to molecular targeted drugs, antibody-based drugs, and immune checkpoint inhibitors, which are developed using new technologies. However, the increasing cost of new drug development is increasing the costs of national healthcare and putting pressure on government finances worldwide. Under these circumstances, drug repositioning (i.e. discovering novel effects of existing drugs, thereby allowing their use to treat other diseases) has become a major focus because of reliability and cost reduction. It is becoming in...
Source: European Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Review Article: Lifestyle Source Type: research
PMID: 31420840 [PubMed - as supplied by publisher]
Source: Pathology Oncology Research - Category: Pathology Authors: Tags: Pathol Oncol Res Source Type: research
The relationship between statin use and the risk of ovarian or endometrial cancer remains controversial. Here, we investigated the relationship between statin use and the risk of ovarian and endometrial cancers.
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Authors: Kobayashi Y, Banno K, Kunitomi H, Tominaga E, Aoki D Abstract Ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer mortality in women. Although standard chemotherapy is the established treatment for ovarian cancer, the prognosis remains poor, and it is highly anticipated that new drugs will be developed. New drugs, such as humanized anti-vascular endothelial growth factor monoclonal antibodies and poly ADP-ribose polymerase inhibitors, are expected to improve clinical outcomes of ovarian cancer. However, long-term, costly research is required to develop such new drugs...
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
(MedPage Today) -- All histologic types of ovarian cancer risk lowered in statin versus non-statin users
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
Ovarian cancer is one of the most lethal cancers and women with type 2 diabetes (T2D) have even poorer survival from it. We assessed the prognosis of ovarian cancer in women with type 2 diabetes treated with m...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Cell plasticity of ‘stem-like’ cancer-initiating cells (CICs) is a hallmark of cancer, allowing metastasis and cancer progression. Here, we studied whether simvastatin, a lipophilic statin, could impair the metastatic potential of CICs in high-grade serous ovarian cancer (HGS-ovC), the most lethal among the gynecologic malignancies. qPCR, immunoblotting and immunohistochemistry were used to assess simvastatin effects on proteins involved in stemness and epithelial-mesenchymal cell plasticity (EMT). Its effects on tumor growth and metastasis were evaluated using different models (e.g., spheroid formation and mig...
Source: Endocrine-Related Cancer - Category: Endocrinology Authors: Tags: Research Source Type: research
More News: Cancer | Cancer & Oncology | Cholesterol | Ovarian Cancer | Ovaries | Science | Statin Therapy | Study | Universities & Medical Training | Women